Inferra AI / Company / QGEN

Qiagen N.V.

QGEN · Health Care

Last earnings Aug 7, 2026

Key results

Revenuequarter

$13.6 million

During the three and six months ended June 30, 2025, we satisfied the associated performance obligations and recognized revenue of $13.6 million and $45.7 million, respectively, related to advance customer payments previously received.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

During the three and six months ended June 30, 2024, we satisfied the associated performance obligations and recognized revenue of $23.0 million and $49.3 million, respectively, related to advance customer payments previously received.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

AI analysis

Q2 2025 · reported Aug 21, 2025

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

Revenue · Q2 2025

$13.6M

EX-99 · Aug 21, 2025

Headline figures

Metric	Q2 2025	Prior qtr	Year ago
Revenue	$13.6 million	—	—

EX-99 · Aug 21, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Revision of Previously Issued Financial Statements During the second quarter of 2025, we corrected the classification of $498.4 million of debt previously reported as long-term as of December 31, 2024 that should have been classified as current under U.

GAAP due to the December 17, 2025 bondholder put date with respect to the $500.0 million aggregate principal amount of 0.000% Senior Unsecured Convertible Notes due 2027.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Qiagen N.V. Q2 2025 — During the three and six months ended June 30, 2025, we satisfied the associated performance obligations and recognized revenue of $13.6 million and $45.7 million, respectively, related to advance cus…

Based on: Earnings release (6-K exhibit) + parent 6-K — transcript not held

Guidance & outlook

No guidance located in the held release

Capital allocation

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

GAAP due to the December 17, 2025 bondholder put date with respect to the $500.0 million aggregate principal amount of 0.000% Senior Unsecured Convertible Notes due 2027.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

The net proceeds of the 2031 Notes totaled $494.2 million, after debt issuance costs of $5.8 million.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Debt issuance costs are amortized to interest expense over the term of the 2031 Notes.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

In connection with the July 2025 dividend payment discussed in Note 13 Equity, the conversion price per share was adjusted to $63.6890.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Convertible Notes due 2027 On December 17, 2020, we issued zero coupon convertible notes in an aggregate principal amount of $500.0 million with a maturity date of December 17, 2027 (2027 Notes).

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Strategy & priorities

Non-Marketable Investments We have made strategic investments in certain privately-held companies without readily determinable market values.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Derivatives and Hedging Objective and Strategy In the ordinary course of business, we use derivative instruments, including swaps, forwards and or options, to manage potential losses from foreign currency exposures and interest-bearing assets or liabilities.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Financial Instruments and Fair Value Measurements Assets and liabilities are measured at fair value according to a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows Level 1.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Risks & headwinds

While changing conditions in our global environment present additional uncertainty, we continue to use the best information available to form our estimates.

SEC original ↗Qiagen N.V. — Earnings release (6-K exhibit)EX-99Aug 21, 2025

Competitors